Filtered By:
Condition: Heart Attack
Management: WHO

This page shows you your search results in order of date.

Order by Relevance | Date

Total 85 results found since Jan 2013.

News at a glance: A win for obesity drugs, NIH unionization roadblocks, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: ScienceNOW - August 10, 2023 Category: Science Source Type: news

News at a glance: A win for obesity drugs, a new infectious disease institute head, and Mexican fireflies under threat
CONSERVATION Researchers raise alarm over threat to Mexican fireflies Scientists from the International Union for Conservation of Nature (IUCN) last week delivered a letter to the Mexican government requesting it regulate tourism centered on the threatened firefly species Photinus palaciosi . Endemic to Mexico’s Tlaxcala forests, P. palaciosi is one of the few species that glow in synchrony, offering an annual spectacle that attracts thousands of visitors during summer mating season. The letter describes how littering, artificial light, and noise interfere with the insects’ courtship and eg...
Source: Science of Aging Knowledge Environment - August 10, 2023 Category: Geriatrics Source Type: research

New Urban Health ‘Accelerator’ Aims to Transform Cardiovascular Population Health Globally
ihadmin2May 22, 2023May 22, 2023GenevaThe CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.Results of initial programs in S ão Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% of heart attacks during implementation.Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world ’s leading cause of death,according to the World Health O...
Source: IntraHealth International - May 22, 2023 Category: International Medicine & Public Health Authors: ihadmin2 Source Type: news

Remote ischaemic preconditioning versus no remote ischaemic preconditioning for vascular and endovascular surgical procedures
CONCLUSIONS: Overall, compared with no RIPC, RIPC probably leads to little or no difference in perioperative mortality, myocardial infarction, renal impairment, stroke, hospital stay, and operating time, and may lead to little or no difference in limb loss in people undergoing elective major vascular and endovascular surgery. Adequately powered and designed randomised studies are needed, focusing in particular on the clinical endpoints and patient-centred outcomes.PMID:36645250 | DOI:10.1002/14651858.CD008472.pub3
Source: Cochrane Database of Systematic Reviews - January 16, 2023 Category: General Medicine Authors: Fuxiang Liang Shidong Liu Guangzu Liu Hongxu Liu Bing Song Liang Yao Qi Wang Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages
Int J Mol Sci. 2022 Jul 5;23(13):7461. doi: 10.3390/ijms23137461.ABSTRACTCardiovascular disease (CVD) is causing high mortality worldwide (World Health Organization-WHO, 2015). Atherosclerosis, the hardening and narrowing of arteries caused by the accumulation of fatty acids and lipids (cholesterol plaques), is a main reason of stroke, myocardial infarction, and angina. Present therapies for cardiovascular disease basically use statins such as β-Hydroxy β-methylglutaryl-CoA, with <70% efficacy and multiple side effects. An in vitro investigation was conducted to evaluate the impact of kaempferol, a natural medicat...
Source: Atherosclerosis - July 9, 2022 Category: Cardiology Authors: Etimad Huwait Maha Ayoub Sajjad Karim Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
Med Sci Monit. 2022 May 1;28:e937048. doi: 10.12659/MSM.937048.ABSTRACTThe consequences of SARS-CoV-2 infection include short-term, long-term, mild, and severe clinical symptoms. The cardiovascular system, including endothelial cells, vascular smooth muscle cells, and cardiac myocytes, are important targets for SARS-CoV-2. In February 2022, the findings from a large US cohort of individuals diagnosed with COVID-19 and two sets of control cohorts evaluated the risk and 12-month cardiovascular disease burden. Individuals who had COVID-19 had a 72% increased risk of heart failure, a 63% increased risk of myocardial infarction...
Source: Medical Science Monitor - May 1, 2022 Category: Research Authors: Dinah V Parums Source Type: research

Calcium channel blockers versus other classes of drugs for hypertension
CONCLUSIONS: For the treatment of hypertension, there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs. There is low to moderate certainty evidence that CCBs probably reduce major cardiovascular events more than beta-blockers. There is low to moderate certainty evidence that CCBs reduced stroke when compared to angiotensin-converting enzyme (ACE) inhibitors and reduced myocardial infarction when compared to angiotensin receptor blockers (ARBs), but increased congestive heart failure when compared to ACE inhibitors and ARBs. Many of the differences ...
Source: Cochrane Database of Systematic Reviews - January 9, 2022 Category: General Medicine Authors: Jiaying Zhu Ning Chen Muke Zhou Jian Guo Cairong Zhu Jie Zhou Mengmeng Ma Li He Source Type: research

Renal denervation for resistant hypertension
CONCLUSIONS: In patients with resistant hypertension, there is low-certainty evidence that renal denervation does not improve major cardiovascular outomes and renal function. Conversely, moderate-certainty evidence exists that it may improve 24h ABPM and diastolic office-measured BP. Future trials measuring patient-centred instead of surrogate outcomes, with longer follow-up periods, larger sample size and more standardised procedural methods are necessary to clarify the utility of this procedure in this population.PMID:34806762 | DOI:10.1002/14651858.CD011499.pub3
Source: Cochrane Database of Systematic Reviews - November 22, 2021 Category: General Medicine Authors: Anna Pisano Luigi Francesco Iannone Antonio Leo Emilio Russo Giuseppe Coppolino Davide Bolignano Source Type: research